BioNexus Gene Lab Corp. (BGLC) Operating margin 2018–2025
BioNexus Gene Lab Corp. (BGLC) operating margin by fiscal year — reported operating income divided by reported revenue.
-39.9%FY2025 · since FY2018: 28.2% → -39.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -39.9% | -23.4 pp |
| FY2024 | -16.5% | +10.0 pp |
| FY2023 | -26.5% | -23.9 pp |
| FY2022 | -2.7% | -10.6 pp |
| FY2021 | 7.9% | -3.3 pp |
| FY2020 | 11.2% | +228.4 pp |
| FY2019 | -217.2% | -245.4 pp |
| FY2018 | 28.2% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice